Weekly dose-dense paclitaxel and carboplatin in recurrent ovarian carcinoma: A phase II trial
Conclusion Weekly TC is active and well-tolerated in platinum-resistant and platinum-sensitive patients with recurrent EOC previously treated with TC given every 3weeks.
Source: Journal of the Egyptian National Cancer Institute - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Epithelial Cancer | Hematology | Neurology | Ovarian Cancer | Ovaries | Peripheral Neuropathy | Study | Toxicology